Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Moderna, Inc. (“Moderna” or “the Company”) (NASDAQ: MRNA) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the “Class Period”). Such investors are encouraged to join this case.

Case Details

The Compliant alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) mRNA-1345 was less effective than Defendants had led investors to believe; (2) accordingly, mRNA-1345’s clinical and/or commercial prospects were overstated; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

What’s Next?

A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. If you suffered a loss in Moderna you have until October 8, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.